comprehensive -WSS

comprehensive

author：fashion 2025-09-06 01:59:37 - browse：3

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

WSS

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Cano Health’s bankruptcy is a warning for Medicare Advantage

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

A protest over insulin prices is seen as a fight for life

Celiac disease study examines precisely how gluten triggers injury

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

How to save PrEP access — and even expand it

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

After affirmative action ruling, medical educators look to 'holistic review'

Top private equity targets in 2023: cardiology, clinical trials, lasers

Hollywood unions extend contract negotiations for actors

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Jerome Adams on the need for new antivirals for Covid

Adopting new red light myopia treatments may be short

hotspot

Global childhood vaccinations edge closer to pre

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Global cancer cases to surge 77% by 2050, WHO report says

Federal judge rules Oregon’s tough new gun law is constitutional

Argenx drug significantly slows progression of nerve disorder

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

hotspot

entertainment

hotspot

focus